Last Update 08 Apr 26

AVNT: Future Crude Linked Cost Management Will Drive ReRating Potential

Analysts have modestly adjusted their price target on Avient to $48.57, with updated assumptions reflecting a slightly lower discount rate and broadly unchanged expectations for revenue growth, profit margins, and future P/E. Recent Street research cites higher crude linked input costs and mixed sector views, alongside higher individual firm targets up to $52.

Analyst Commentary

Recent notes present a split view on Avient, with some focusing on higher potential value as models roll forward, and others highlighting input cost pressure and sector headwinds. Here is how the Street commentary broadly breaks down.

Bullish Takeaways

Bullish analysts who lifted targets into the low to mid US$40s and low US$50s are effectively assigning more value to Avient's projected earnings stream as they roll their models to 2026, which supports the modestly higher blended target around US$48.57.
Several target increases in a short window suggest that, despite mixed sector views, some see Avient's execution as sufficient to support higher fair value assumptions, even if the rating stance stays neutral.
One prior Overweight rating paired with a higher target in the US$50 range pointed to confidence that, if demand normalizes from current levels, Avient could potentially earn into the valuation frameworks being used.
Bullish analysts acknowledge ongoing industry issues, but still assign Avient a target that implies upside from lower historical target levels, reflecting some faith in management's ability to manage through cyclical and structural challenges.

Bearish Takeaways

Bearish analysts who moved to more neutral sector stances cite rising raw material and crude linked input costs, which could pressure margins and make it harder for Avient to fully deliver on current earnings assumptions.
The downgrade from a more positive rating to a Sector Weight profile signals concern that Avient may not stand out relative to peers if commodity costs stay elevated, keeping the risk or reward balance more evenly matched.
Commentary about cyclical construction and durables demand, ongoing commodity capacity overhang, and deindustrialization in key Western markets highlights that the broader chemicals space faces structural issues that could limit how quickly Avient can translate any demand improvement into stronger profitability.
Even where targets were previously raised, the more cautious tone around sector level constraints suggests some analysts see limited room for multiple expansion on Avient's shares unless there is clearer evidence of sustained margin and demand improvement.

What's in the News

From October 1, 2025 to December 31, 2025, Avient reported no share repurchases under its existing buyback authorization, with 0 shares repurchased for US$0 million in that period. (Key Developments)
Across the life of the buyback program announced on August 18, 2008, Avient has completed the repurchase of 35,795,155 shares for a total of US$989.23 million. (Key Developments)
The completed repurchase of 35,795,155 shares represents 40.29% of the intended amount under the long running buyback, indicating that the authorization has been materially utilized over time. (Key Developments)

Valuation Changes

Fair Value: $48.57 is unchanged, with the updated model keeping the same implied fair value level.
Discount Rate: The discount rate has fallen slightly from 8.54% to 8.36%, which modestly increases the present value assigned to future cash flows.
Revenue Growth: The revenue growth assumption is effectively unchanged at around 3.53%, indicating similar expectations for top line expansion.
Net Profit Margin: The net profit margin assumption remains steady at about 7.28%, pointing to stable profitability expectations in the model.
Future P/E: The future P/E is marginally lower, moving from 21.45x to 21.34x, reflecting a slightly more conservative earnings multiple applied to Avient.

2 views

Key Takeaways

Expansion into high-value healthcare and sustainable materials, plus strong innovation, positions Avient for resilient growth, improved profit margins, and premium-product pricing.
Operational efficiencies and strategic debt reduction increase free cash flow, lower risk, and support ongoing investment in innovation and long-term value creation.
Secular declines in key markets, raw material volatility, regulatory and sustainability pressures, and over-reliance on select sectors threaten Avient's growth, profitability, and long-term valuation.

Catalysts

About Avient

Operates as a formulator of material solutions in the United States, Canada, Mexico, Europe, South America, and Asia.What are the underlying business or industry changes driving this perspective?

Accelerating demand for high-performance, specialty materials in healthcare devices, drug delivery, and equipment-driven by global healthcare expansion and innovative new product launches-positions Avient for resilient, long-term revenue growth and increased net margins due to higher-value, spec-in solutions.
Continued shift in customer and regulatory preferences toward eco-friendly lightweight polymers and sustainable materials, along with Avient's portfolio transformation and innovation in low-energy, circular products, supports future revenue expansion and structural improvement in EBITDA margins.
Enhanced R&D collaboration, evidenced by rising patent filings and successful proprietary product introductions, is expanding Avient's differentiated solutions pipeline-supporting higher gross profit and long-term earnings power as new products command premium pricing.
Ongoing footprint optimization, Lean Six Sigma initiatives, and discretionary spending controls are structurally lowering operating costs and improving productivity-leading to sustained improvements in EBITDA margins and higher free cash flow generation.
Strategic deleveraging of the balance sheet enables increased capacity for reinvestment in growth vectors like healthcare and sustainability, reducing financial risk and supporting stronger EPS growth and enterprise value over the long term.

Avient Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Avient's revenue will grow by 3.5% annually over the next 3 years.
Analysts assume that profit margins will increase from 2.5% today to 7.3% in 3 years time.
Analysts expect earnings to reach $263.5 million (and earnings per share of $3.5) by about April 2029, up from $81.9 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 21.6x on those 2029 earnings, down from 38.9x today. This future PE is lower than the current PE for the US Chemicals industry at 28.2x.
Analysts expect the number of shares outstanding to grow by 0.1% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.36%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Sustained weakness and broad-based decline in consumer end-markets across all major geographies, with no near-term signs of improvement, could restrain top-line revenue growth and represent a structural risk if secular consumption patterns continue to shift away from traditional polymer-based goods.
Exposure to volatility and inflation in the raw material basket, especially pigments and flame retardants (a significant portion sourced from China), may lead to persistent cost pressure; inability to fully pass through these increases to customers could compress net margins and earnings.
Ongoing regulatory shifts, trade policy uncertainty, and potential supply constraints-particularly in China, where government-enforced consolidation and credit tightening disrupt supply chains-risk increasing input costs or reducing demand, jeopardizing revenue stability and profitability.
Dependence on strong performance in high-growth sectors like healthcare, defense, and telecom to offset persistent weakness in core markets introduces concentration risk; any deceleration or regulatory headwind in these sectors could quickly erode overall earnings momentum.
Continued broad investor, customer, and regulatory focus on sustainability might outpace Avient's innovation and portfolio transformation efforts; prolonged legacy exposure to non-sustainable or commodity polymers could limit contract wins and revenue scalability, raising the risk of long-term stagnation in net income and impairing valuation.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $48.57 for Avient based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.6 billion, earnings will come to $263.5 million, and it would be trading on a PE ratio of 21.6x, assuming you use a discount rate of 8.4%.
Given the current share price of $34.72, the analyst price target of $48.57 is 28.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Avient?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

High-Performance Healthcare Materials And Sustainable Polymers Will Create Value